Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Price

TNXPStock

$6.04−67.89%52W

Market Cap$103.59M

P/E—

PEG Ratio—

Div yield—

Beta1.89

TNXP Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-64.66%

Price vs S&P 500 (4W)-42.33%

VGM Score57.26

Book Value / Share (Quarterly)$13.24

P/TBV (Annual)0.82x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-9.42

Price vs S&P 500 (YTD)-73.26%

Gross Margin (TTM)83.83%

Net Profit Margin (TTM)-548.64%

EPS (TTM)$-12.92

10-Day Avg Trading Volume1.33M

EPS Excl Extra (TTM)$-12.92

EPS (Annual)$-14.57

ROI (Annual)-50.59%

Gross Margin (Annual)49.34%

Cash / Share (Quarterly)$10.49

Revenue Growth QoQ (YoY)577.88%

ROA (Last FY)-44.75%

Revenue Growth TTM (YoY)196.02%

EBITD / Share (TTM)$-12.78

ROE (5Y Avg)-69.94%

Operating Margin (TTM)-568.43%

Cash Flow / Share (Annual)$-8.07

P/B Ratio0.47x

P/B Ratio (Quarterly)0.92x

Net Income / Employee (Annual)$-873,400

EV / Revenue (TTM)-2.50x

Net Interest Coverage (TTM)-2.39x

ROA (TTM)-61.32%

EPS Incl Extra (Annual)$-14.57

Current Ratio (Annual)7.42x

Quick Ratio (Quarterly)6.13x

3-Month Avg Trading Volume0.60M

52-Week Price Return-67.89%

Revenue / Employee (TTM)$204,900

Tangible BV / Share (Quarterly)$13.23

P/S Ratio (Annual)7.90x

Asset Turnover (Annual)0.05x

52-Week High$20.69

EPS Excl Extra (Annual)$-14.57

CapEx CAGR (5Y)-17.01%

Tangible BV CAGR (5Y)91.96%

26-Week Price Return-54.76%

Quick Ratio (Annual)6.99x

13-Week Price Return-51.41%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.61x

Enterprise Value$-72.64M

Asset Turnover (TTM)0.11x

Book Value / Share Growth (5Y)-26.22%

Revenue / Employee (Annual)$92,300

Pretax Margin (Annual)-946.22%

Cash / Share (Annual)$16.24

3-Month Return Std Dev66.47%

Net Income / Employee (TTM)$-1,124,400

ROE (Last FY)-50.59%

Net Interest Coverage (Annual)-421.14x

EPS Basic Excl Extra (Annual)$-14.57

Receivables Turnover (TTM)4.12x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-12.92

ROI (TTM)-68.99%

P/S Ratio (TTM)3.56x

Revenue / Share (Annual)$1.54

Tangible BV / Share (Annual)$19.16

Price vs S&P 500 (52W)-83.42%

Year-to-Date Return-61.33%

5-Day Price Return-9.04%

EPS Normalized (Annual)$-14.57

ROA (5Y Avg)-57.45%

Net Profit Margin (Annual)-946.22%

Month-to-Date Return-37.99%

Cash Flow / Share (TTM)$-10.41

EBITD / Share (Annual)$-14.79

Operating Margin (Annual)-975.01%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-67.27%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-12.92

P/TBV (Quarterly)0.92x

P/B Ratio (Annual)0.81x

Inventory Turnover (TTM)0.88x

Pretax Margin (TTM)-548.64%

Book Value / Share (Annual)$19.17

Price vs S&P 500 (13W)-54.09%

Beta1.89x

Revenue / Share (TTM)$1.75

ROE (TTM)-68.99%

52-Week Low$6.01

gGradeA

mGradeD

vgmGradeC

TNXP Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 10, 2026	-$2.62	-$2.47	+5.58%(+$0.15)
Q1 2026	May 11, 2026	-$2.54	-$2.93	-15.35%(-$0.39)
Q4 2025	Mar 12, 2026	-$2.94	-$3.98	-35.44%(-$1.04)
Q3 2025	Nov 10, 2025	-$2.75	-$3.70	-34.45%(-$0.95)
Q2 2025	Aug 11, 2025	-$1.88	-$4.00	-112.76%(-$2.12)

TNXP Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.11

4.20

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
TNXPTonix Pharmaceuticals Holding Corp.	—	A	D	3.6x	196.0%	83.8%	—	$6.04
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals is a commercial-stage biotech company developing treatments for CNS disorders and immunological conditions. Its approved product TONMYA treats fibromyalgia, while marketed migraine medications Zembrace SymTouch and Tosymra provide current revenue. The company is expanding TONMYA into depression and acute stress disorder through clinical trials and advancing a pipeline including TNX-4800 for Lyme disease prevention and TNX-1500 for transplant rejection prevention.